Role of Ranolazine in cardiovascular disease and diabetes: Exploring beyond angina

Area of Science:

• Cardiology
• Pharmacology

Background:

• Ranolazine is FDA-approved for chronic angina, with its mechanism of action involving late sodium current inhibition.
• Research has expanded beyond angina to explore ranolazine's effects in other cardiovascular and metabolic conditions.

Purpose of the Study:

• To review current research on ranolazine's potential applications beyond its approved indication for chronic angina.
• To highlight promising areas such as atrial fibrillation, diabetes, and cardiotoxicity.

Main Methods:

• Literature review of studies investigating ranolazine's efficacy and mechanisms in various conditions.
• Analysis of clinical trial data and research findings on ranolazine's expanded therapeutic potential.

Main Results:

• Ranolazine demonstrates potential in managing atrial fibrillation, particularly post-coronary artery bypass grafting (CABG) and recurrent cases.
• The drug shows significant HbA1c lowering effects in diabetic patients with coronary artery disease.
• Emerging evidence suggests possible benefits in pulmonary arterial hypertension, diastolic dysfunction, and chemotherapy-induced cardiotoxicity.

Conclusions:

• Ranolazine exhibits a broader therapeutic profile than initially approved for chronic angina.
• Further large-scale, randomized phase III trials are essential to validate these emerging indications and fully understand ranolazine's clinical utility.